Filament Health Announces Pre-IND Meeting With United States Food And Drug Administration Post published:April 12, 2022 Post category:Press Release
Filament Health Announces Second Patent Issuance Post published:March 23, 2022 Post category:Press Release
Filament Health and ATMA Journey Centers Announce Licensing Agreement Post published:February 23, 2022 Post category:Press Release
Filament Health Subsidiary Psilo Scientific Announces Inclusion in Health Canada List of Licensed Psilocybin Producers Post published:January 26, 2022 Post category:Press Release
Filament Health and Cybin Therapeutics Announce Licensing Agreement Post published:January 17, 2022 Post category:Press Release
Filament Health Announces Health Canada Approval for Phase II Trial Administering New Psilocybin Microdose Formulation Post published:January 4, 2022 Post category:Press Release
Filament Health Announces Co-Development and Exclusive Licensing Agreement with Entheotech Bioscience Post published:November 18, 2021 Post category:Press Release
Filament Health Reports Third Quarter 2021 Financial Results and Operational Highlights Post published:November 15, 2021 Post category:Press Release
Filament Health Announces FDA Authorization of Clinical Trial with First-Ever Direct Psilocin Administration and First-Ever Psychedelic Botanical Drug Candidates Post published:November 2, 2021 Post category:Press Release
Filament Health Shares to Commence Trading on the OTC Market Post published:September 7, 2021 Post category:Press Release